AustriaAustria

Intercell expands into mAB market

10.07.2010

Vienna – Austria’s Intercell AG has closed the acquisition of Cytos’ platform technology for monoclonal antibody discovery, which is based on expression cloning of monoclonal antibodies from human B-cells. As per agreed terms, the first installment of a10m of the purchase price has been already paid. The second installment of a5m is unconditional, and is due at the end of next January. With the licensing agreement, Intercell says it intends to complement its Antigen Identification Program (AIP®). The deal could provide a viable basis for the development of novel and more powerful prophylact­ic and therapeutic vaccines, as well as antibody treatments. The company says it also opens up novel medical and commercially relevant applications for AIP®, which has been successfully applied in the identification of a large number of novel antigens from several pathogenic organisms.

Tech Review

12.03.2010

How much of you is you? In the habitat of the human body, the percentage of cells bearing your genetically distinct DNA is in the clear minority, vastly outnumbered by a host of microbes. Only around a tenth of the estimated 100...

BioPeople

12.03.2010

French immunology specialist TxCell S.A. (Valbonne) has appointed Miguel Forte as its Chief Medical Officer. Forte, who worked at UCB, Bristol-Myers Squibb and Nabi Pharmaceuticals, will be responsible for the clinical...

Clinical Trial

11.03.2010

Martinsried – German autoimmune and cancer specialist 4SC AG has started enrolment of 30 patients with incurable cancers for a Phase I study of its oral Eg5 kinesin spindle protein inhibitor 4SC-205. The dose-finding study will...

Clinical Trial

11.03.2010

Lachen – Swiss Octapharma AG has kicked-off the first of a series of pivotal Phase III studies for its new 10% high purity intravenous immunoglobulin (IVIG) in primary immune deficiency. The 5% solution of human recombinant...

Tech Review

11.03.2010

Genome engineering specialist Cellectis designs and markets meganucleases, which enable targeted modifications to DNA, with three primary aims: understanding, production and treatment. The technology platform surrounding these...

BioPeople

11.03.2010

BioPhausia (Stockholm) CEO Claes Thulin is leaving his post after 8 years in order to pursue other entrepreneurial activities. The change is supported by the company’s board, which has already begun the process of recruiting a...

Tech Review

10.03.2010

Molsheim – With a volume of US$36.687bn, according to the latest market report from Datamonitor, therapeutic monoclonal antibodies (mAbs) were once again the most important class of bio­pharmaceuticals in business terms in 2009....

Clinical Trial

10.03.2010

Basel – Amgen‘s RANKL blocker Prolia (denosumab) has achieved primary and secondary endpoints in a Phase III head-to-head comparison with Novartis’ bisphosphonate Zometa (zoledronic acid) in patients with bone metastases from...

Clinical Trial

10.03.2010

London – The European Medicines Agency (EMA) has outlined its strategy for facing current regulatory challenges. A 22-page draft for public consultation entitled “The European Medicines Agency Road Map to 2015 – the Agency’s...

Clinical Trial

10.03.2010

Basel/London – The EMA and Swissmedic have agreed to confidentially share information on post-marketing safety and efficacy issues related to H1N1 vaccines and drugs in mid-February.

Displaying results 311 to 320 out of 1983

< Previous 311-320 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive/browse/31/article/intercell-expands-into-mab-market.html

Print Magazine

Event Video

All videos

Events

All Events

Stock list

All quotes

TOP

  • EPIGENOMICS4.34 EUR11.57%
  • PAION2.86 EUR10.85%
  • STRATEC BIOMEDICAL41.92 EUR3.92%

FLOP

  • CYTOS0.15 CHF-6.25%
  • MAGFORCE5.40 EUR-6.09%
  • CO.DON2.70 EUR-5.26%

TOP

  • BIOFRONTERA2.84 EUR29.1%
  • EPIGENOMICS4.34 EUR13.3%
  • VITA 344.42 EUR7.5%

FLOP

  • MAGFORCE5.40 EUR-21.7%
  • CYTOS0.15 CHF-16.7%
  • CO.DON2.70 EUR-14.0%

TOP

  • SANTHERA89.00 CHF2260.7%
  • CO.DON2.70 EUR181.3%
  • PAION2.86 EUR125.2%

FLOP

  • CYTOS0.15 CHF-96.1%
  • THERAMETRICS0.07 CHF-50.0%
  • 4SC0.94 EUR-44.4%

No liability assumed, Date: 29.10.2014


Current issue

All issues

Product of the week

Products